卡帕塞替尼片Capivasertib 200mg

Capivasertib is an enzyme inhibitor indicated for use in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer harboring one or more PIK3CA/AKT1/PTEN alterations.

Recommended Dose: 400 mg orally twice daily, administered for 4 consecutive days followed by a 3-day treatment-free interval. Administration Instructions: May be taken with or without food.

Patients with known hypersensitivity to any component of this product.

Blood Glucose Monitoring: Monitor blood glucose regularly during treatment. Reduce the dose or discontinue the medication based on the severity of hyperglycemia if it occurs. Diarrhea Management: Monitor patients for signs and symptoms of diarrhea. Advise patients to increase oral fluid intake and initiate antidiarrheal therapy at the first sign of diarrhea during treatment. Severe Cutaneous Adverse Reactions: Severe cutaneous adverse reactions may occur during treatment. Embryo-Fetal Toxicity Female patients should use effective contraceptive measures during treatment and for 1 month after the last dose. Male patients should use effective contraceptive measures during treatment and for 4 months after the last dose. Pregnancy and Lactation: Use with caution in pregnant women and lactating women. Concomitant Use with Fulvestrant: Pay attention to the contraindications of fulvestrant when used in combination.

Diarrhea, cutaneous adverse reactions, elevated random blood glucose, decreased lymphocytes, decreased hemoglobin, elevated fasting blood glucose, nausea, fatigue, leukopenia, increased triglycerides, neutropenia, elevated creatinine, vomiting, stomatitis.

64 tablets per bottle.

Store in a tightly sealed container, protected from moisture and light, at room temperature (20℃–25℃). Short-term excursions between 15℃ and 30℃ are permitted. Keep out of the reach of children.